Roots Analysis

FEBRUARY 20, 2022

In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads to failure in obtaining approval authorization. Nanoparticles Contract Manufacturing.

Contract Manufacturing 52

Contract Manufacturing Bioavailability Manufacturing Drug Delivery Systems 52

The Pharma Data

JANUARY 7, 2021

The pharmaceutical product landscape is rapidly and fundamentally changing with profound impact on research and development strategy and technology needs. The number of biopharmaceutical products show a considerable growth accounting for nearly a quarter of the new molecular entities approved in 2017.

Bioavailability 52

Bioavailability Production Manufacturing Drugs 52

Pharmaceutical Technology

AUGUST 22, 2022

When it comes to pharmaceutical, nutritional or cosmeceutical dosing, some of the most crucial parameters are safety, product effectiveness and patient adherence. They also offer enhanced bioavailability, exact dosing and an extended shelf life. billion by 2028, at a CAGR of 12.6%.

Compliance 130

Compliance Bioavailability Containment Branding 130

pharmaphorum

JANUARY 16, 2023

The bi-weekly intramuscular shot – which was also approved in China in 2021 – will enter a crowded market for long-acing injectable (LAI) schizophrenia therapies in the US and have to take on heavyweight competition, including drugs that require less frequent dosing.

FDA Approval 52

FDA Approval Drugs Bioavailability Marketing 52

Cloudbyz

MARCH 5, 2024

The difference between biologics vs small molecules in pharma drug development In pharmaceutical drug development, biologics and small molecules represent two distinct categories of medicinal products, each with their own unique characteristics, development processes, and mechanisms of action.

Development 75

Development Drugs Manufacturing Immune Response 75

Roots Analysis

MARCH 2, 2022

One of the key objectives behind the aforementioned developments is to overcome issues related to high costs associated with the design and production of such pharmacological interventions. The Oral Protein and Peptides Market is anticipated to grow at a CAGR of over 20%, during 2022-2032. Oral Protein / Peptide-based Drugs.

Protein 52

Protein Drug Delivery Drugs Drug Delivery Systems 52

Delveinsight

FEBRUARY 16, 2021

Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry. Takeda wins big in cytomegalovirus infection market.

Marketing 52

Marketing Protein Bioavailability Drugs 52

The Pharma Data

DECEMBER 9, 2020

Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets,” Feinberg said at the time of the launch. It’s like taking out the trash.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

Roots Analysis

OCTOBER 2, 2023

Additionally, it increases the bioavailability and solubility of the attached molecule. In fact, in the last twenty years, the United States Food and Drug Administration (USFDA) and the European Medicines Agency (EMA) have authorized the market approval of around 80 nanomedicines.

Drug Delivery 40

Drug Delivery Drugs Bioavailability Marketing 40

Roots Analysis

MARCH 13, 2022

In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide. Furthermore, excipients play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs).

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Roots Analysis

SEPTEMBER 1, 2023

By charting new waters and creating uncontested market spaces, companies can differentiate themselves and unlock unprecedented growth opportunities. In this blog post, I’ll explore how pharma / biotech companies can leverage the blue ocean and red ocean strategy to make waves in the market.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

Camargo

SEPTEMBER 30, 2021

Drug product formulation should be as simple as possible, but carefully executed to account for the characteristics of the intended administration route and dosing regimen and to facilitate successful manufacturing, storage, shipping, and compliance in the clinic and eventually on the market. CMC Considerations. Unstable intermediates.

Development 201

Development Research Manufacturing In-Vivo 201

pharmaphorum

AUGUST 19, 2022

If all goes well, the aim is to bring resiniferatoxin to market in 2025. ” Grünenthal already sells a topical capsaicin product called Qutenza for post-shingles nerve pain and diabetic nerve pain affecting the feet, and recently started a phase 3 trial that aims to extend its indications to include post-surgical neuropathic pain. .

Drugs 52

Drugs Bioavailability Trials Clinical Development 52

XTalks

FEBRUARY 3, 2023

Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics and a wholly owned subsidiary of the Menarini Group, will market Orserdu in the US. ER+, HER2- Breast Cancer ER+, HER2- cancers account for about 75 percent of breast cancers.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

Delveinsight

JULY 30, 2020

The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 In patients with CALD, Adrenoleukodystrophy market offers two therapies, namely Lorenzo’s oil and haematopoietic stem cell transplantation (HSCT) , using either umbilical cord stem cells or bone marrow stem cells.

Hormones 52

Hormones Marketing Gene Trials 52

Drug Discovery World

JULY 25, 2023

Long term clinical neurodevelopment safety studies The FDA has issued guidance for developing long-term clinical neuro-developmental safety studies for products intended for neonates. The goal of these studies is to inform the safety of neonatal product development and improve outcomes for this vulnerable population.

Development 52

Development Drugs Medicine Production 52

The Pharma Data

JANUARY 3, 2021

to have in place 25 operating production lines of which 5 to 10 are expected to be GMP production lines. The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. over 90 percent gross margin. to be cash flow positive.

Containment 52

Containment Bioavailability Clinical Trials Clinical Trials 52

Delveinsight

JANUARY 7, 2021

The startup recently raised USD 87 million to propel itself in a competitive market. Ribometrix will also be eligible to obtain potential milestone payments exceeding USD 1 billion and tiered royalties on future global net sales of products that ensue from the collaboration. Terns raises USD 87 Million for NASH drugs.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. ” Prof. Finnish time. About Nanoform. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

Containment 52

Containment Medicine Bioavailability Clinical Trials 52

The Pharma Data

JANUARY 20, 2021

Part B is designed to be a confirmatory post-market approval observational trial to confirm long-term renal protection and assess the difference in kidney function between treated and placebo patients as measured by eGFR over a two-year period from the start of dosing of each patient. It also showed that Nefecon was generally well-tolerated.

Trials 52

Trials Containment Clinical Trials Clinical Trials 52

Pharmaceutical Technology

MAY 31, 2023

It is expected to accelerate the development of CFT8919 in important international markets. CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC).

Bioavailability 130

Bioavailability In-Vivo In-Vitro Licensing 130

The Pharma Data

NOVEMBER 19, 2020

These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies. This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

Development 40

Development Bioavailability Production Drugs 40

Delveinsight

AUGUST 10, 2020

Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. Boehringer Ingelheim is worth mentioning here, as it is presenting key posters and studies on Ofev’s SENSCIS Trial and INBUILD Trial. Ofev (Nintedanib) Facts. Ofev (Nintedanib) Approval History.

Drugs 52

Drugs Trials Bioavailability FDA Approval 52

Drug Discovery World

DECEMBER 7, 2022

By Dr Natalia Dadivanyan , Segment Marketing Manager, Malvern Panalytical . Despite the emergence of, and excitement around, advanced therapeutic modalities, traditional small molecule pharmaceuticals still occupy a significant and steadily growing share of the market. Small molecules can face big challenges .

Bioavailability 52

Bioavailability Manufacturing Production Development 52

The Pharma Data

DECEMBER 1, 2020

The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. Axsome’s core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14.

Trials 52

Trials Clinical Trials Clinical Trials Production 52

Pharmaceutical Technology

NOVEMBER 24, 2022

We asked them to explain how the company has integrated its isotopic labeling and human ADME testing services to help streamline the drug development process and accelerate the time it takes to get drugs to market. This has proved to be an extremely effective option for molecules where an understanding of absolute bioavailability is required.

Bioavailability 130

Bioavailability Manufacturing Drugs Production 130

The Pharma Data

DECEMBER 3, 2020

Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. In transplant recipients, reactivation of CMV can lead to serious consequences including loss of the transplanted organ and, in extreme cases, can be fatal.

Drugs 52

Drugs Medicine Trials Containment 52

Pharmaceutical Technology

AUGUST 3, 2022

Yet commercialising a drug is no easy journey, hence why just 10% of new drug candidates succeed in making it to market. During this stage, a team of lab technicians must identify the best way to manufacture the active pharmaceutical ingredient (API) into a suitable dosage form for pilot production.

Development 130

Development Production Manufacturing Bioavailability 130

Pharmaceutical Technology

OCTOBER 25, 2022

Understanding both the significant competitive advantages that FDC products can offer, and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. More FDC products flowing into pharma pipelines.

Manufacturing 130

Manufacturing Production Packaging Packaging 130

The Pharma Data

MARCH 11, 2021

Presentation Title: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD). Sintilimab injection is not an approved product in the United States. Session Date and Time: Monday, April 12, 2021 1:30 PM – 3:15 PM ET. Abstract Number: 1236. About Sintilimab.

Research 52

Research Clinical Trials Clinical Trials Trials 52

Drug Discovery World

AUGUST 9, 2023

The development of Ritonavir Ritonavir is a drug for the treatment of Acquired Immuno-Deficiency Syndrome (AIDS) marketed in 1996. This is critical in understanding and anticipating cases where the solid form of the drug can change to a different polymorphic form within the formulated product.

Research 52

Research Bioavailability Scientist Drugs 52

XTalks

AUGUST 30, 2022

Global sales of over-the-counter and prescription products related to central nervous system (CNS) disease added up to $86 billion in 2019. Consider targeting your therapies that fail to be orally bioavailable and brain penetrant. Why is it Difficult to Develop CNS Therapeutics? The patients are waiting!

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

DECEMBER 3, 2020

SOL-578 is a best-in-class checkpoint kinase 1 (Chk1) inhibitor featuring high kinase selectivity and oral bioavailability which targets the DNA Damage Response (DDR) network. We believe that PharmaEngine can accelerate the development of this product based on our successful experience with a liposomal irinotecan, Onivyde®.”

Licensing 52

Licensing Licensing Bioavailability DNA 52

pharmaphorum

NOVEMBER 22, 2021

Gilead Sciences has submitted its marketing application for bulevirtide, its antiviral therapy for rare hepatitis delta virus (HDV) infections, to the FDA. If approved, bulevirtide will be the first drug to be approved in the US for HDV , a virus that exists only as a co-infection with hepatitis B virus (HBV).

Bioavailability 64

Bioavailability Marketing Drugs Vaccination 64

Pharmaceutical Technology

JUNE 26, 2022

Placing traditionally siloed drug substance and drug product development activities within a single organization that also has commercial manufacturing capabilities accelerates clinical development and builds in quality and robustness of supply. Streamlined processes to reduce time to market for drugs. Polymorphic form issues.

Manufacturing 130

Manufacturing Drugs Production Development 130

The Pharma Data

JANUARY 27, 2021

As a bioscience accelerator at the leading-edge of the life science industry, XPhyto targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation. . VANCOUVER, BC / ACCESSWIRE / January 28, 2021 / XPhyto Therapeutics Corp.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

The Pharma Data

MAY 14, 2021

Product Name: ProstaStream. If within the first 60 days of receipt you are not satisfied with Wake Up Lean , you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked. ClickBank is the retailer of products on this site.

Packaging 52

Packaging Packaging Production Bioavailability 52